M9140

DRUG7 trials

Conditions

Colorectal CancerGastric CancerMetastatic colorectal cancerNon-Small Cell Lung CancerNon-Small Cell Lung Cancer (NSCLC)Pancreatic CancerPancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

RecruitingNCT05464030

EMD Serono Research & Development Institute, Inc.Colorectal Cancer

Start: 2022-08-04End: 2026-10-23Target: 200Updated: 2026-07-02

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Active, not recruitingNCT06710132

EMD Serono Research & Development Institute, Inc.Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer +2

Start: 2025-01-29End: 2027-12-23Target: 250Updated: 2026-05-28

Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

Active, not recruitingNCT06806046

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyColorectal Cancer, Solid Tumors

Start: 2024-12-20End: 2026-09-30Updated: 2026-05-22

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Pancreatic Cancer (Substudy PDAC)

RecruitingCTIS2024-517819-74-00

Merck Healthcare KGaAPancreatic Ductal Adenocarcinoma

Start: 2025-06-02Target: 21Updated: 2025-12-22

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC)

RecruitingCTIS2024-517817-34-00

Merck Healthcare KGaAGastric Cancer

Start: 2025-06-18Target: 45Updated: 2025-12-22

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC)

RecruitingCTIS2024-517818-15-00

Merck Healthcare KGaANon-Small Cell Lung Cancer

Start: 2025-06-06Target: 51Updated: 2025-12-22

Phase 3

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Not yet recruitingCTIS2025-524648-37-00

Merck Healthcare KGaAMetastatic colorectal cancer

Target: 170Updated: 2026-07-15

Journal of Clinical Oncology2026-05-27

Precemtabart tocentecan (Precem-TcT, M9140) in patients with mCRC: Efficacy and safety data at the recommended development dose in the PROCEADE-CRC-01 study.

Journal of Clinical Oncology2026-01-10

Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial.

2025-07-30

Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study.

Journal of Clinical Oncology2025-05-281 citations

PROCEADE PanTumor: A phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors.

Journal of Clinical Oncology2025-05-28

Abstract CT117: PROCEADE PanTumor: A Phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors

Cancer Research2025-04-25

First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2024-06-019 citations

Abstract 2362: Preclinical efficacy and safety of M9140, a novel antibody-drug conjugate (ADC) with topoisomerase 1 (TOP1) inhibitor payload targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing colorectal tumors

Cancer Research2024-03-223 citations

M9140

Sponsors

Conditions

Phase 1

Phase 3

Related Papers